Gates alumnus addresses FDA hearing on neglected diseases

  • October 14, 2010
Gates alumnus addresses FDA hearing on neglected diseases

Dr Andrew Robertson has spoken at a US FDA hearing on research into neglected diseases.

A Gates alumnus has given testimony to a Food and Drug Administration hearing in the US on how to develop drugs for the world’s poorest people.

Dr Andrew Robertson, co-founder of the Gates Scholars Alumni Association and Gates Scholars Council and a Trustee of the Gates Cambridge Trust, gave evidence in September to a FDA hearing on neglected disease research.

Dr Robertson, Chief Policy Officer at BIO Ventures for Global Health, spoke at the FDA’s “Advancing the Development of Medical Products Used in the Prevention, Diagnosis, and Treatment of Neglected Tropical Diseases” hearing. BVGH is a Gates Foundation-funded organisation that works to involve biotech in addressing global health challenges.

The promotion of innovation in neglected tropical disease research is a key issue for BVGH. During his testimony, Dr Robertson was joined by representatives from other non-profits in advocating for certain improvements to the Government’s Priority Review Voucher program, a new system to provide pharmaceutical companies with the financial incentives to create drugs for the world’s poorest patients.

Over 1 billion people — one sixth of the world’s population — suffer from one or more neglected tropical diseases.

Dr Robertson called for reforms to the PRV system, such as the inclusion of certain diseases like Chagas disease on the PRV-eligible list, and emphasised the need for FDA guidance that helps companies understand the requirements for earning a PRV, as well as guidance that helps companies assess the value and strategies for use of the voucher. He added that the success of the programme depends on the participation of the biopharmaceutical industry.

The PRV programme aims to offset drug development for neglected tropical diseases (NTD). In return for developing a drug or vaccine for an NTD, such as tuberculosis or malaria, companies are rewarded with a transferable voucher entitling them to FDA priority review for a drug of their choice, such as a cholesterol-lowering drug.  This voucher can reduce the FDA approval process by four to twelve months, and has estimated to be worth between $50 and $500 million to pharmaceutical firms.  However, there are concerns that, while the scheme is elegant in design, its implementation by the FDA has created serious barriers to being adopted by industry.

Dr Robertson says: “My experience during and after the FDA meeting speaks volumes about the need for better communication with drug makers. Numerous representatives from biopharmaceutical companies and product development partnerships approached me, saying that they were very interested in the PRV program but wanted to know more. They want to understand how the program is implemented and determine how they can use it to either reimburse or supplement the cost of their ongoing research. There is a clear need to inform, consult, and guide drug researchers about how to take advantage of the PRV program.”

More information

Dr Robertson’s blog on the hearing 

Picture credit: jscreationzs and www.freedigitalphotos.net

 

Latest News

Affecting change for the Māori community

Self-determination lies at the centre of Māori culture. “It’s a way of life,” says Chris Tooley. That idea is also at the heart of his PhD studies at Cambridge and his subsequent work in Parliament and in the community. Chris grew up with a strong sense of being part of the Māori community. He has ancestral […]

On the COVID frontline

Three Gates Cambridge scholars who have been on the medical frontline during the COVID-19 pandemic will be speaking about their experiences at a virtual event next weekend. The event, organised by the Gates Cambridge Alumni Association, will be moderated by Elizabeth Dzeng, Assistant Professor of Medicine at the University of California, San Francisco in the […]

New game tackles Covid conspiracies

A new online game that puts players in the shoes of a purveyor of fake pandemic news is the latest tactic in the UK Government’s efforts to tackle the deluge of coronavirus misinformation that is misleading many and costing lives across the world. Launched to the public today, the Go Viral! game has been developed by the […]

“Democracy does not work on a ‘trust me’ basis”

When Jennifer Gibson started her MPhil at Cambridge in 2001 as part of the inaugural class of Gates Scholars, no-one knew what it meant to be a Gates Cambridge Scholar. Twenty years later, Jennifer is now a human rights lawyer focused on national security issues, something she never could have anticipated, but which she credits in no small part […]